Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

SkyCity claims it is entitled to $330m in damages from Fletcher Building
Markets

SkyCity claims it is entitled to $330m in damages from Fletcher Building

The original delivery date of the International Convention Centre was January 2019. 

10 NZ firms could get slice of $200m Fisher KiwiSaver cash
Markets

10 NZ firms could get slice of $200m Fisher KiwiSaver cash

Private equity investing will benefit both KiwiSavers and business, fund manager says.